Market Place
Sourcing Support
Abivax To Present Data On Obefazimod At Digestive Disease Week
22 Apr 2026 //
GLOBENEWSWIRE
Abivax Unveils Obefazimod`s Anti-Fibrotic Activity In IBD
21 Feb 2026 //
GLOBENEWSWIRE
Abivax shares soar 23% as media report reignites M&A Chatters
11 Jan 2026 //
REUTERS
Abivax To Be Added To Nasdaq Biotechnology Index
18 Dec 2025 //
GLOBENEWSWIRE
Abivax Presents Third Quarter 2025 Financial Results
15 Dec 2025 //
GLOBENEWSWIRE
Abivax Ph3 Obefazimod Data Show QoL Gains in Ulcerative Colitis
03 Nov 2025 //
GLOBENEWSWIRE
Abivax Presents 8-Week ABTECT Data From Late-Breaking Session
06 Oct 2025 //
GLOBENEWSWIRE
Abivax Presents 8-Week ABTECT Trial Results With Safety Update
05 Oct 2025 //
GLOBENEWSWIRE
Abivax To Present Late-Breaking Abtect Phase 3 Data At 2025 UEG
29 Sep 2025 //
GLOBENEWSWIRE
Abivax Presents Obefazimod ABTECT Ph 3 Trials at 2025 UEG Meeting
23 Sep 2025 //
GLOBENEWSWIRE
Abivax Joins CAC Mid 60, SBF 120 Indices After Euronext Review
12 Sep 2025 //
GLOBENEWSWIRE
Abivax Reveals H1 2025 Financial Results
08 Sep 2025 //
GLOBENEWSWIRE
Abivax Fully Exercises Underwriters` Option, Raising $747.5 M
25 Jul 2025 //
GLOBENEWSWIRE
Abivax Halts Trading of Ordinary Shares on Euronext Paris
24 Jul 2025 //
GLOBENEWSWIRE
Abivax Prices $650M Public Offering of American Depositary Shares
24 Jul 2025 //
GLOBENEWSWIRE
Abivax Aces Phase 3 Colitis Trials as End of Cash Runway Looms
24 Jul 2025 //
FIERCE BIOTECH
Abivax Launches Public Offering
23 Jul 2025 //
GLOBENEWSWIRE
Abivax Reveals Ph3 Results for Obefazimod in Ulcerative Colitis
22 Jul 2025 //
GLOBENEWSWIRE
Abivax Announces Results of June 6, 2025 Meeting
11 Jun 2025 //
GLOBENEWSWIRE
Abivax Completes Enrollment for Ph 3 Trials in Ulcerative Colitis
29 Apr 2025 //
GLOBENEWSWIRE
Abivax Appoints Dominik Höchli, MD to Board of Directors
22 Apr 2025 //
GLOBENEWSWIRE
Abivax Sets AGM as 2025 Milestones Approach
22 Apr 2025 //
GLOBENEWSWIRE
Abivax Announces Full Year 2024 Financial Results
24 Mar 2025 //
GLOBENEWSWIRE
Abivax Publishes 2025 Financial Calendar
28 Jan 2025 //
GLOBENEWSWIRE
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
09 Jan 2025 //
GLOBENEWSWIRE
Abivax Announces a Change to Composition of its Board of Directors
23 Dec 2024 //
GLOBENEWSWIRE
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19 Nov 2024 //
GLOBENEWSWIRE
Abivax presents third quarter 2024 key financial information
14 Nov 2024 //
GLOBENEWSWIRE
Abivax Appoints Mark Stenhouse as Board Observer & Advisor
13 Nov 2024 //
GLOBENEWSWIRE
Abivax Congratulates Nobel Prize Winners For microRNA Discovery
07 Oct 2024 //
GLOBENEWSWIRE
Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study
03 Oct 2024 //
GLOBENEWSWIRE
Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn`s Disease
03 Oct 2024 //
GLOBENEWSWIRE
Abivax To Present Obefazimod Abstracts At UEG Week 2024
26 Sep 2024 //
GLOBENEWSWIRE
Abivax Updates On UC Combination Therapy Program Strategy
25 Sep 2024 //
GLOBENEWSWIRE
Abivax presents first-half 2024 financial results
09 Sep 2024 //
GLOBENEWSWIRE
Two biotechs go public while Apnimed bides its time
02 Oct 2023 //
FIERCE BIOTECH
Lexeo and Abivax seek Nasdaq listings in shrinking window for biotech IPOs
29 Sep 2023 //
ENDPTS
